BR0314635A - Derivados de piridina como moduladores de receptores de cb2 - Google Patents

Derivados de piridina como moduladores de receptores de cb2

Info

Publication number
BR0314635A
BR0314635A BR0314635-9A BR0314635A BR0314635A BR 0314635 A BR0314635 A BR 0314635A BR 0314635 A BR0314635 A BR 0314635A BR 0314635 A BR0314635 A BR 0314635A
Authority
BR
Brazil
Prior art keywords
pyridine derivatives
receptor modulators
diseases
modulators
receptors
Prior art date
Application number
BR0314635-9A
Other languages
English (en)
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
Karamjit Singh Jandu
William Leonard Mitchell
Alan Naylor
Giovanni Palombi
Derek Anthony Rawlings
Brian Peter Slingsby
Andrew Richard Wainwright
Richard Howard Green
Original Assignee
Glaxo Group Limided
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limided filed Critical Glaxo Group Limided
Publication of BR0314635A publication Critical patent/BR0314635A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE PIRIDINA COMO MODULADORES DE RECEPTORES DE CB2". A presente invenção se refere a derivados inéditos de piridina, a composições farmacêuticas contendo estes compostos e ao seu uso no tratamento de doenças, especialmente da dor, doenças estas que são causadas direta ou indiretamente por um aumento ou redução na atividade do receptor de canabinóides.
BR0314635-9A 2002-09-27 2003-09-25 Derivados de piridina como moduladores de receptores de cb2 BR0314635A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222493.9A GB0222493D0 (en) 2002-09-27 2002-09-27 Compounds
PCT/EP2003/010930 WO2004029026A1 (en) 2002-09-27 2003-09-25 Pyridine derivatives as cb2 receptor modulators

Publications (1)

Publication Number Publication Date
BR0314635A true BR0314635A (pt) 2005-08-02

Family

ID=9944904

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314635-9A BR0314635A (pt) 2002-09-27 2003-09-25 Derivados de piridina como moduladores de receptores de cb2

Country Status (23)

Country Link
US (1) US20060240048A1 (pt)
EP (1) EP1565442B1 (pt)
JP (1) JP2006503845A (pt)
KR (1) KR20050071514A (pt)
CN (1) CN1703402A (pt)
AR (1) AR041395A1 (pt)
AT (1) ATE378317T1 (pt)
AU (1) AU2003268907A1 (pt)
BR (1) BR0314635A (pt)
CA (1) CA2500231A1 (pt)
DE (1) DE60317555T2 (pt)
ES (1) ES2294313T3 (pt)
GB (1) GB0222493D0 (pt)
IS (1) IS7809A (pt)
MA (1) MA27448A1 (pt)
MX (1) MXPA05003263A (pt)
NO (1) NO20052028L (pt)
NZ (1) NZ538943A (pt)
PL (1) PL375990A1 (pt)
RU (1) RU2005112752A (pt)
TW (1) TW200413321A (pt)
WO (1) WO2004029026A1 (pt)
ZA (1) ZA200502084B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
JP2008501758A (ja) 2004-06-09 2008-01-24 グラクソ　グループ　リミテッド ピロロピリジン誘導体
EA200800562A1 (ru) * 2005-08-09 2008-06-30 Глаксо Груп Лимитед Производные имидазопиридина в качестве лигандов каннабиноидного рецептора
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
CA2643863A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
JP5064506B2 (ja) 2006-10-04 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
CN101687117B (zh) * 2007-02-22 2013-06-26 汉默卢斯医药有限责任公司 高容量生物流体过滤设备
KR20110117146A (ko) * 2009-01-22 2011-10-26 라퀄리아 파마 인코포레이티드 Ｃｂ2 수용체 효능활성이 있는 ｎ-치환 포화 헤테로사이클릭 술폰 화합물
RU2011143740A (ru) 2009-03-30 2013-05-10 Астеллас Фарма Инк. Соединение пиримидина
JP5727482B2 (ja) * 2009-08-24 2015-06-03 ニューラルステム， インコーポレイテッド 神経刺激性ピペラジンの合成
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013048962A (ja) * 2012-12-12 2013-03-14 Hemerus Medical Llc 大容量の体液濾過装置
WO2018055640A1 (en) * 2016-09-22 2018-03-29 Srf Limited Process for the preparation of haloalkyl derivatives of nicotinic acid
MA53002A (fr) * 2018-06-27 2021-05-05 Eth Zuerich Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2
EP3813888B1 (en) 2018-06-27 2025-11-26 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
WO2020002280A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2020025574A1 (en) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process
EP3666759A1 (en) 2018-12-10 2020-06-17 Bayer Aktiengesellschaft Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands

Also Published As

Publication number Publication date
NZ538943A (en) 2007-01-26
JP2006503845A (ja) 2006-02-02
AU2003268907A1 (en) 2004-04-19
WO2004029026A1 (en) 2004-04-08
CN1703402A (zh) 2005-11-30
EP1565442A1 (en) 2005-08-24
TW200413321A (en) 2004-08-01
ES2294313T3 (es) 2008-04-01
NO20052028L (no) 2005-06-03
EP1565442B1 (en) 2007-11-14
ZA200502084B (en) 2006-02-22
ATE378317T1 (de) 2007-11-15
AR041395A1 (es) 2005-05-18
PL375990A1 (en) 2005-12-12
KR20050071514A (ko) 2005-07-07
RU2005112752A (ru) 2006-01-20
US20060240048A1 (en) 2006-10-26
MA27448A1 (fr) 2005-07-01
DE60317555T2 (de) 2008-10-23
CA2500231A1 (en) 2004-04-08
DE60317555D1 (de) 2007-12-27
MXPA05003263A (es) 2005-07-05
IS7809A (is) 2005-04-19
GB0222493D0 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
BRPI0511874A (pt) derivados da pirrolopiridina
DE60309739D1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
BRPI0409977A (pt) derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfato
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
PA8493701A1 (es) Compuestos para tratar la obesidad
BR0110486A (pt) Antranilamidas e sua aplicação como medicamento
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
BRPI0512634A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BR0112093A (pt) Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
BR0215801A (pt) Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
BR0208053A (pt) Sìntese de moléculas isoflavonas diméricas, composições contendo as mesmas e seus usos como agentes terapêuticos
BR0214141A (pt) Derivados de piperidina e seu uso como moduladores da atividade de receptor de quimiocina (especialmente ccr5)
BRPI0408689A (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
BRPI0408389A (pt) derivados de cromeno como agentes antiinflamatórios
AU2003260436A1 (en) Pyrimidine compounds
WO2007049158A3 (en) Ppar modulating biaromatic compounds
BR0214046A (pt) Derivados de pirazol como substâncias psicofarmacêuticas
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.